Cellectis (CLLS) Cash from Investing Activities (QoQ) (2015 - 2026)
Powered by 
Analysis
Cellectis (CLLS) Cash from Investing Activities (QoQ) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 403.52% |
| Mar 31, 2026 | -127.46% |
| Dec 31, 2025 | 752.46% |
| Sep 30, 2025 | 93.47% |
| Jun 30, 2025 | -1,348.33% |
| Mar 31, 2025 | 125.35% |
| Dec 31, 2024 | -174.60% |
| Sep 30, 2024 | 120.98% |
| Jun 30, 2024 | -5,089.13% |
| Mar 31, 2024 | 84.98% |
| Dec 31, 2023 | -4,451.00% |
| Sep 30, 2023 | 83.04% |
| Jun 30, 2023 | -1,430.08% |
| Mar 31, 2023 | 146.83% |
| Dec 31, 2022 | -156.13% |
| Sep 30, 2022 | 127.34% |
| Jun 30, 2022 | -169.83% |
| Mar 31, 2022 | 93.87% |
| Dec 31, 2021 | -354.92% |
| Sep 30, 2021 | -125.51% |